Teladoc Health (TDOC) under pressure after Q4 earnings, JPMorgan analyst Lisa Gill reaffirms neutral rating, price target $11. Revenue estimate of $617.5 million for Q1.
Telemedicine specialist Teladoc Health (TDOC 1.53%) has been a terrible investment over the past three years. Once the ...
Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ETCompany ParticipantsLaure Park - Senior Vice President ...
UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...
(DOCU) on Thursday ...
(RGLS) on ...
Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of ...
StockStory.org on MSN4d
A Look Back at Online Marketplace Stocks’ Q4 Earnings: Shutterstock (NYSE:SSTK) Vs The Rest Of The PackAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Good day and thank you for standing by. Welcome to the Telos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback